drugset / Trial / NCT05308901
Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma
Phase 2
Active not recruiting
6 enrolled
Providence Health & Services
Eisai Inc. · collabMerck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy of lenvatinib and pembrolizumab to treat metastatic uveal melanoma.
Timeline
- Start
- 2022-08-02
- Primary completion
- 2024-12-03
- Completion
- 2027-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenvatinib | Small molecule | 20 mg | — |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |